1.
Richardson PG, Perrot A, Miguel JS, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang S-Y, Minarik J, Cavo M, Prince HM, Macé S, Zhang R, Dubin F, Morisse MC, Anderson KC. Isatuximab-pomalidomide-dexamethasone <i>versus</i&gt; pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis. haematol [Internet]. 2020Sep.10 [cited 2024Apr.20];. Available from: https://haematologica.org/article/view/haematol.2023.284325